Brief Description
4D Molecular Therapeutics is a global leader in gene therapy product research and development using scientific innovation to unlock the full potential of gene therapy for patients with genetic diseases. Their robust discovery platform, termed Directed Vector Evolution, empowers creation of customized gene delivery vehicles (novel AAV vectors) to deliver normal genes to tissues or organs with defective genes. as occurs in genetic diseases. This 4DMT discovery technology was originally developed over 15 years by co-Founder David Schaffer at UC Berkeley.
Inventors
Company Founders
UC Berkeley Professor David Schaffer, David Kirn (UC Berkeley, Bachelor of Arts, 1985, Physiology & Physical Anthropology), Melissa Kotterman (UC Berkeley, Ph.D., 2013, Chemical and Biomolecular Engineering), Theresa Janke
Timeline
- 2013. Company founded
- 2020. Initial public offering on the Nasdaq stock exchange under the symbol of FDMT